Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807207 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02807207: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT02807207 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02807207, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the cardiac safety of a single oral dose (400 mg) of pacritinib compared to placebo on the QT calculated using the Fridericia correction (QTcF) interval in healthy subjects.
Interventions
- DRUG A: pacritinib
- OTHER B: Placebo
- DRUG C: moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02807207
The ClinicalTrials.gov registry entry for NCT02807207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which A: pacritinib is the first listed.
NCT02807207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02807207 about?
NCT02807207 is a clinical study titled "To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects". The primary objective is to evaluate the cardiac safety of a single oral dose (400 mg) of pacritinib compared to placebo on the QT calculated using the Fridericia correction (QTcF) interval in healthy subjects.
What is the current status of trial NCT02807207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2014-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02807207?
The interventions under investigation include: A: pacritinib (DRUG), B: Placebo (OTHER), C: moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT02807207?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.